Financial Ratios Quoin Pharmaceuticals, Ltd.
Equities
QNRX
US74907L4095
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.398 USD | +0.81% |
|
-1.09% | -63.13% |
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | -87.18 | -70.6 | -48.59 | -44.03 | -42.72 | |
Return on Total Capital | 21.07 | 159.99 | -68.43 | -56.58 | -55.88 | |
Return On Equity % | 37.69 | 721.4 | -232.68 | -132.92 | -120.55 | |
Return on Common Equity | 37.69 | 721.4 | -234.3 | -132.92 | -120.55 | |
Short Term Liquidity | ||||||
Current Ratio | 0.06 | 1.02 | 3.79 | 3.15 | 3.57 | |
Quick Ratio | 0.04 | 0.9 | 3.64 | 2.99 | 3.36 | |
Operating Cash Flow to Current Liabilities | -0.17 | -0.69 | -2.4 | -2.2 | -1.88 | |
Long Term Solvency | ||||||
Total Debt/Equity | -18.36 | - | 55.68 | 62.21 | 31.76 | |
Total Debt / Total Capital | -22.49 | - | 35.76 | 38.35 | 24.11 | |
LT Debt/Equity | - | - | 47.57 | 51.62 | 25.25 | |
Long-Term Debt / Total Capital | - | - | 30.56 | 31.82 | 19.16 | |
Total Liabilities / Total Assets | 579.55 | 92.98 | 48.77 | 53.46 | 41.41 | |
EBIT / Interest Expense | -35.52 | -4.44 | -12.96 | - | - | |
EBITDA / Interest Expense | -33.3 | -4.36 | -12.82 | - | - | |
(EBITDA - Capex) / Interest Expense | -33.3 | -4.36 | -12.82 | - | - | |
Total Debt / EBITDA | -0.77 | - | -0.45 | -0.38 | -0.31 | |
Net Debt / EBITDA | -0.57 | 1.26 | 0.95 | 0.77 | 1.18 | |
Total Debt / (EBITDA - Capex) | -0.77 | - | -0.45 | -0.38 | -0.31 | |
Net Debt / (EBITDA - Capex) | -0.57 | 1.26 | 0.95 | 0.77 | 1.18 | |
Growth Over Prior Year | ||||||
EBITDA, 1 Yr. Growth % | 1.7 | 280.52 | 53.62 | 1.32 | 1.66 | |
EBITA, 1 Yr. Growth % | 1.7 | 280.52 | 53.62 | 1.32 | 1.66 | |
EBIT, 1 Yr. Growth % | 7.02 | 263.04 | 52.7 | 1.3 | 1.6 | |
Earnings From Cont. Operations, 1 Yr. Growth % | 34.28 | 924.29 | -56.29 | -7.41 | 3.18 | |
Net Income, 1 Yr. Growth % | 34.28 | 924.29 | -56.29 | -7.41 | 3.18 | |
Normalized Net Income, 1 Yr. Growth % | 10.04 | 1.08K | -51.53 | -11.34 | 3.18 | |
Diluted EPS Before Extra, 1 Yr. Growth % | - | - | - | - | -80.17 | |
Total Assets, 1 Yr. Growth % | 35.52 | 579.11 | 54.52 | -15.83 | 29.09 | |
Tangible Book Value, 1 Yr. Growth % | 36.02 | -97.98 | -4.52K | -24.19 | 71.66 | |
Common Equity, 1 Yr. Growth % | 46.44 | -109.94 | 1.03K | -23.53 | 62.51 | |
Cash From Operations, 1 Yr. Growth % | 3.06 | 327.31 | 48.26 | -7.27 | -0.09 | |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | -18.6 | -24.62 | -8.73 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | -18.25 | -18.79 | -8.73 | |
Compound Annual Growth Rate Over Two Years | ||||||
EBITDA, 2 Yr. CAGR % | - | 96.73 | 141.77 | 24.76 | 1.49 | |
EBITA, 2 Yr. CAGR % | - | 96.73 | 141.77 | 24.76 | 1.49 | |
EBIT, 2 Yr. CAGR % | - | 97.12 | 135.45 | 24.37 | 1.45 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 270.87 | 111.6 | -36.38 | -2.26 | |
Net Income, 2 Yr. CAGR % | - | 270.87 | 111.6 | -36.38 | -2.26 | |
Normalized Net Income, 2 Yr. CAGR % | - | 259.91 | 138.87 | -34.44 | -4.36 | |
Total Assets, 2 Yr. CAGR % | - | 203.37 | 223.94 | 14.04 | 4.24 | |
Tangible Book Value, 2 Yr. CAGR % | - | -83.44 | -5.59 | 478.96 | 14.07 | |
Common Equity, 2 Yr. CAGR % | - | -61.84 | 5.88 | 193.61 | 11.48 | |
Cash From Operations, 2 Yr. CAGR % | - | 109.86 | 151.7 | 17.26 | -3.75 | |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | -21.67 | -17.06 | |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | -18.52 | -13.91 | |
Compound Annual Growth Rate Over Three Years | ||||||
EBITDA, 3 Yr. CAGR % | - | - | 81.16 | 80.93 | 16.53 | |
EBITA, 3 Yr. CAGR % | - | - | 81.16 | 80.93 | 16.53 | |
EBIT, 3 Yr. CAGR % | - | - | 81.03 | 77.75 | 16.26 | |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 81.84 | 60.64 | -25.26 | |
Net Income, 3 Yr. CAGR % | - | - | 81.84 | 60.64 | -25.26 | |
Normalized Net Income, 3 Yr. CAGR % | - | - | 84.48 | 71.67 | -23.74 | |
Total Assets, 3 Yr. CAGR % | - | - | 142.27 | 106.71 | 18.85 | |
Tangible Book Value, 3 Yr. CAGR % | - | - | 6.63 | -12.25 | 286.06 | |
Common Equity, 3 Yr. CAGR % | - | - | 17.97 | -5.01 | 141.07 | |
Cash From Operations, 3 Yr. CAGR % | - | - | 86.91 | 80.44 | 11.16 | |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | -17.57 | |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | -15.38 | |
Compound Annual Growth Rate Over Five Years | ||||||
EBITDA, 5 Yr. CAGR % | - | - | - | - | 43.68 | |
EBITA, 5 Yr. CAGR % | - | - | - | - | 43.68 | |
EBIT, 5 Yr. CAGR % | - | - | - | - | 43.6 | |
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | 41.85 | |
Net Income, 5 Yr. CAGR % | - | - | - | - | 41.85 | |
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 41.85 | |
Total Assets, 5 Yr. CAGR % | - | - | - | - | 72.9 | |
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 9.55 | |
Common Equity, 5 Yr. CAGR % | - | - | - | - | 15.33 | |
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | 43.33 |
- Stock Market
- Equities
- QNRX Stock
- Financials Quoin Pharmaceuticals, Ltd.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition